Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Rarbar99 greatest hits LOL!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Post by Inthepezon Aug 20, 2021 10:23am
125 Views
Post# 33739354

Rarbar99 greatest hits LOL!

Rarbar99 greatest hits LOL! Rarbar99 greatest hits that have been debunked in the AGM:

-“Today's report was the final nail in the coffin”
-“its over. It's not speculation. If the company knew this was all fudd and an overreaction”
-“5x liver transaminase levels is VERY DANGEROUS. This is not a small side-effect or a bad reaction, this is very serious and there is no way it's just an "outlier" that can be brushed off.”

and people call him out on his BS, his response is: 

-“And just so y'all know, I'm not a short. I only discovered this company after it crashed and I own 25,000 shares at average price of $1.07”

and of course my personal favourite LOL:

”I usually don't show off and I hate people who do, but I feel like I have to put some of you in your place. how does it make you feel seeing a 22 year old drive a $240,000 2021 G63 AMG?”

just be sure not be like that incel trust fund kid who murdered those innocent people. Get back on your meds asap. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities